Callan JMB signs support services deal with Cavalry 1838 Equine Biosciences for 60% revenue share

Callan JMB signed a strategic support services agreement with Cavalry 1838 Equine Biosciences to support commercialization at the Atlas Complex.

• The deal gives Callan JMB a 60% participation in enterprise revenue, expanding its recurring infrastructure services business.
• The base-case plan targets annual revenue of USD 12 million to USD 25 million within seven years for the enterprise.
• Alabama operations will be based at the Atlas Complex, with Kansas set as the primary serum collection and production site.